SCHEMBL4258940

SCHEMBL4258940

O=C(O)c1ccc(C(=O)C=Cc2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.69
CYP1B1 Q16678 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP1A1 P04798 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
DHODH Q02127 1/20 0.57
CXCL12 P48061 3/20 0.56
XDH P47989 1/20 0.55
GUSB P08236 1/20 0.55
TSHR P16473 1/20 0.55
MAPT P10636 2/20 0.53
MITF O75030 1/20 0.53
RECQL P46063 1/20 0.53
RAB9A P51151 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
SRD5A2 P31213 1/20 0.53
MAOB P27338 2/20 0.53
PYGL P06737 1/20 0.53
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258938 1.00 PTGS2 (0.69) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL30382766 0.89 PTGS2 (0.71) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL1225523 0.89 PTGS2 (0.71) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL656338 0.89 CYP1B1 (0.69) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL1225524 0.89 PTGS2 (0.71) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL656339 0.89 CYP1B1 (0.69) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL25199743 0.87 PTGS2 (0.69) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL7304255 0.87 PTGS2 (0.69) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL31233368 0.87 PTGS2 (0.69) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2
SCHEMBL7308126 0.87 PTGS2 (0.69) PTGS2CYP1B1CYP3A4CYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-01-22 US disclosed
US-7282608-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2007-10-16 US disclosed
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2006-01-26 US disclosed
EP-1551795-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2005-07-13 EP disclosed
WO-2004035525-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC6 PTGS2 2686/4885CYP1B1 4130/4885CYP3A4 4615/4885
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B PTGS2 704/4885CYP1B1 230/4885CYP3A4 928/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 PTGS2 330/4885CYP1B1 1027/4885CYP3A4 1589/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 PTGS2 330/4885CYP1B1 1027/4885CYP3A4 1589/4885
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents HDAC1, AADAC, HDAC11 PTGS2 2183/4885CYP1B1 2294/4885CYP3A4 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.